Sanofi ROA 2012-2025 | SNY
Current and historical return on assets (ROA) values for Sanofi (SNY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Sanofi ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2025-09-30 | $10.21B | $151.72B | 7.09% |
| 2025-06-30 | $10.03B | $141.85B | 9.45% |
| 2025-03-31 | $6.76B | $138.95B | 6.40% |
| 2024-12-31 | $6.02B | $143.70B | 8.49% |
| 2024-09-30 | $4.91B | $0.00B | 7.11% |
| 2024-06-30 | $4.57B | $139.73B | 6.60% |
| 2024-03-31 | $4.93B | $0.00B | 7.21% |
| 2023-12-31 | $5.84B | $136.87B | 8.55% |
| 2023-09-30 | $9.68B | $0.00B | 14.33% |
| 2023-06-30 | $9.02B | $136.69B | 13.35% |
| 2023-03-31 | $8.71B | $0.00B | 13.23% |
| 2022-12-31 | $8.82B | $133.51B | 13.41% |
| 2022-09-30 | $8.33B | $0.00B | 25.69% |
| 2022-03-31 | $6.88B | $0.00B | 20.32% |
| 2021-09-30 | $6.90B | $0.00B | 20.40% |
| 2021-03-31 | $7.99B | $0.00B | 0.00% |
| 2020-09-30 | $7.39B | $0.00B | 0.00% |
| 2020-03-31 | $6.36B | $0.00B | 0.00% |
| 2019-09-30 | $4.98B | $0.00B | 17.65% |
| 2019-03-31 | $4.86B | $0.00B | 17.22% |
| 2018-03-31 | $4.71B | $0.00B | 8.37% |
| 2017-12-31 | $9.53B | $112.83B | 16.96% |
| 2017-09-30 | $9.90B | $0.00B | 17.37% |
| 2017-06-30 | $9.92B | $112.08B | 17.41% |
| 2017-03-31 | $10.09B | $0.00B | 17.71% |
| 2016-12-31 | $5.21B | $115.83B | 9.15% |
| 2016-09-30 | $6.19B | $0.00B | 22.10% |
| 2016-06-30 | $5.76B | $111.96B | 10.46% |
| 2016-03-31 | $5.52B | $0.00B | 9.48% |
| 2015-09-30 | $4.90B | $0.00B | 5.45% |
| 2015-06-30 | $4.59B | $108.32B | 3.75% |
| 2014-06-30 | $5.57B | $124.45B | 5.83% |
| 2013-06-30 | $6.39B | $126.66B | 6.44% |
| 2012-06-30 | $8.61B | $130.75B | 12.74% |
| 2012-03-31 | $8.56B | $0.00B | 12.10% |
| 2011-12-31 | $9.33B | $139.51B | 13.20% |
| 2011-09-30 | $8.04B | $0.00B | 12.53% |
| 2011-06-30 | $7.45B | $143.31B | 11.62% |
| 2011-03-31 | $8.22B | $0.00B | 14.73% |
| 2010-12-31 | $8.24B | $113.22B | 14.76% |
| 2010-09-30 | $9.30B | $0.00B | 16.78% |
| 2010-06-30 | $10.37B | $110.06B | 18.71% |
| 2010-03-31 | $11.38B | $0.00B | 21.05% |
| 2009-12-31 | $10.99B | $111.64B | 20.34% |
| 2009-09-30 | $9.57B | $0.00B | 18.20% |
| 2009-06-30 | $8.26B | $104.55B | 15.69% |
| 2009-03-31 | $7.76B | $0.00B | 14.67% |
| 2008-12-31 | $7.76B | $105.92B | 14.69% |
| 2008-09-30 | $9.72B | $0.00B | 19.04% |
| 2008-06-30 | $10.42B | $105.54B | 20.42% |
| 2008-03-31 | $9.21B | $0.00B | 18.44% |
| 2007-12-31 | $8.40B | $98.57B | 16.82% |
| 2007-09-30 | $6.95B | $0.00B | 13.97% |
| 2007-06-30 | $6.45B | $101.22B | 12.98% |
| 2007-03-31 | $7.18B | $0.00B | 14.36% |
| 2006-12-31 | $6.99B | $97.69B | 13.97% |
| 2006-09-30 | $6.79B | $0.00B | 12.91% |
| 2006-06-30 | $6.95B | $102.44B | 13.22% |
| 2006-03-31 | $6.66B | $0.00B | 12.08% |
| 2005-12-31 | $5.54B | $107.92B | 10.05% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $112.219B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |